Get the Stockscreener App
49.74
1.24%
0.61
Qiagen Nv stock is traded at $49.74, with a volume of 847.55K.
It is up +1.24% in the last 24 hours and up +0.46% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$49.13
Open:
$49.11
24h Volume:
847.55K
Relative Volume:
0.62
Market Cap:
$10.55B
Revenue:
$1.98B
Net Income/Loss:
$83.59M
P/E Ratio:
132.99
EPS:
0.374
Net Cash Flow:
$502.31M
1W Performance:
+0.79%
1M Performance:
+0.46%
6M Performance:
+25.70%
1Y Performance:
+3.51%
1-Day Range:
$49.09
$49.96
1-Week Range:
$48.62
$49.96
52-Week Range:
$37.74
$51.88
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
49.74 | 10.55B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
What makes Qiagen N.V. stock price move sharply2025 Stock Rankings & Verified Swing Trading Watchlists - thegnnews.com
QIAGEN NV : Gets a Buy rating from Deutsche Bank - MarketScreener
Qiagen Manager Sells $1.23M in Shares for Asset Allocation - AInvest
QIAGEN Executive Sells Significant Shareholding - TipRanks
Qiagen Executive Sells Significant Shareholding - TipRanks
QIAGEN Manager Sells Shares for Asset Allocation - TipRanks
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR - TradingView
QIAGEN N.V. Announces Managerial Share Sale by Roland Sackers - TipRanks
Qiagen N.V. Reversal Rally May Surprise Bears2025 Stock Rankings & Fast Moving Market Watchlists - metal.it
Upbeat Q2 Results and Raised Outlook Could Be a Game Changer for Qiagen (QGEN) - simplywall.st
Sector Leaders Rotate Capital Into Qiagen N.V.July 2025 Spike Watch & AI Based Buy/Sell Signal Reports - newsyoung.net
Qiagen N.V. shares rise 1.09% intraday as DAX index climbs toward record high. - AInvest
Will Qiagen N.V. Hold Gains Into CloseJuly 2025 Fed Impact & Growth Focused Investment Plans - sundaytimes.kr
Sentiment Turns Positive on Qiagen N.V. — Reversal AheadJuly 2025 Movers & Long-Term Capital Growth Strategies - classian.co.kr
PATENT—Fed. Cir.: Qiagen did not infringe Labcorp's DNA sequencing preparation patents; $4.7M jury verdict reversed - VitalLaw.com
How Investors Are Reacting To Qiagen (QGEN) Return to Profitability and Upgraded 2025 Sales Outlook - simplywall.st
Contradictions Unveiled: Qiagen's 2025Q2 Earnings Call Highlights Divergent Views on Market Performance and Growth - AInvest
Is Qiagen N.V. stock showing strong momentumFree Trend Reversal Signals - newsyoung.net
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
STD Diagnostic Market Forecast and Company Analysis Report 2025-2033 Featuring Siemens, Abbott, MedMira, QIAGEN, Danaher, F. Hoffmann-La Roche, Diasorin, BioMeriuex, Hologic, Bio-Rad Laboratories - GlobeNewswire Inc.
Why Qiagen (QGEN) International Revenue Trends Deserve Your Attention - sharewise.com
Investors Interested In Qiagen N.V.'s (NYSE:QGEN) Earnings - 富途牛牛
Europe Molecular Oncology Diagnostics Market Research Report 2024-2033 | Competitive Analysis of Biocartis Group, bioMerieux, F. Hoffmann-La Roche, QIAGEN - Yahoo Finance
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $49 to $50 - 富途牛牛
Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
Why Qiagen N.V. stock attracts strong analyst attentionMulti-Year Breakout Candidates - sisain.net
QIAGEN Reports Strong Q2 2025 Results, Raises Sales Outlook - The Globe and Mail
UBS Adjusts Price Target on QIAGEN to $50 From $48, Maintains Neutral Rating - MarketScreener
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $50 to $55 - 富途牛牛
UBS Maintains Qiagen NV(QGEN.US) With Hold Rating, Announces Target Price $50 - 富途牛牛
Qiagen N.V. (NYSE:QGEN) Q2 2025 Earnings Call Transcript - Insider Monkey
QIAGEN NV : Jefferies maintains a Buy rating - MarketScreener
Qiagen Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Qiagen N.V. shares rise 1.16% premarket after Deutsche Bank reaffirms Buy rating and Q2 earnings beat expectations. - AInvest
QIAGEN Exceeds Q2 2025 Outlook with 7% Sales Growth and Improved Profitability - AInvest
Transcript : Qiagen N.V., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Qiagen: Better than expected Q2; sales guidance upgraded - MarketScreener
QIAGEN NV : Deutsche Bank reaffirms its Buy rating - MarketScreener
Activist investor Fivespan takes stake in QiagenBloomberg - MSN
Qiagen N.V. shares fall 1.22% premarket despite exceeding Q2 2025 outlook with solid growth. - AInvest
Qiagen NV Reports Strong Q2 Earnings, Surpasses Revenue ExpectationsNews and Statistics - IndexBox
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability - BioSpace
Qiagen: Q2 Earnings Snapshot - The Washington Post
Qiagen (QGEN) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
Qiagen NV reports results for the quarter ended June 30Earnings Summary - TradingView
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability | QGEN Stock News - GuruFocus
Qiagen reports Q2 adjusted EPS 62c, consensus 60c - TipRanks
Qiagen reports Q2 2025 net sales $534 million, adjusted EPS $0.6 - MarketScreener
Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk - simplywall.st
What to Expect from Qiagen NV (QGEN) Q2 2025 Earnings - GuruFocus
Can Qiagen N.V. Escape Recent Bear ChannelRisk Managed Trade Playbook Insight - beatles.ru
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):